Pharmacogenetics in the management of coumarin anticoagulant therapy: the way forward or an expensive diversion?

Mike Greaves

doi:10.1371/journal.pmed.0020342

Pharmacogenetics in the management of coumarin anticoagulant therapy: the way forward or an expensive diversion?

Mike Greaves

School of Medicine, Medical Sciences & Nutrition

Research output: Contribution to journal › Editorial › peer-review

19 Citations (Scopus)

4 Downloads (Pure)

Abstract

Warfarin and related coumarin-based anticoagulants are the mainstay of pharmacological management for the long-term prevention of thromboembolism. It is estimated that over 1 million residents in the United Kingdom take warfarin; in excess of 20 million prescriptions for the anticoagulant are dispensed each year in the United States of America. Despite recent advances in the development of novel, alternative, oral antithrombotics it is likely that coumarins will be used widely for at least the next decade.

Original language	English
Article number	e342
Number of pages	2
Journal	PLoS Medicine
Volume	2
Issue number	10
DOIs	https://doi.org/10.1371/journal.pmed.0020342
Publication status	Published - 25 Oct 2005

Access to Document

10.1371/journal.pmed.0020342

Pharmacogentics
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/3.0/
Final published version, 89.2 KB

Cite this

@article{3bdf703c8fc94006af097a5d496cff6d,

title = "Pharmacogenetics in the management of coumarin anticoagulant therapy: the way forward or an expensive diversion?",

abstract = "Warfarin and related coumarin-based anticoagulants are the mainstay of pharmacological management for the long-term prevention of thromboembolism. It is estimated that over 1 million residents in the United Kingdom take warfarin; in excess of 20 million prescriptions for the anticoagulant are dispensed each year in the United States of America. Despite recent advances in the development of novel, alternative, oral antithrombotics it is likely that coumarins will be used widely for at least the next decade.",

author = "Mike Greaves",

year = "2005",

month = oct,

day = "25",

doi = "10.1371/journal.pmed.0020342",

language = "English",

volume = "2",

journal = "PLoS Medicine",

issn = "1549-1277",

publisher = "Nature Publishing Group",

number = "10",

}

TY - JOUR

T1 - Pharmacogenetics in the management of coumarin anticoagulant therapy

T2 - the way forward or an expensive diversion?

AU - Greaves, Mike

PY - 2005/10/25

Y1 - 2005/10/25

N2 - Warfarin and related coumarin-based anticoagulants are the mainstay of pharmacological management for the long-term prevention of thromboembolism. It is estimated that over 1 million residents in the United Kingdom take warfarin; in excess of 20 million prescriptions for the anticoagulant are dispensed each year in the United States of America. Despite recent advances in the development of novel, alternative, oral antithrombotics it is likely that coumarins will be used widely for at least the next decade.

AB - Warfarin and related coumarin-based anticoagulants are the mainstay of pharmacological management for the long-term prevention of thromboembolism. It is estimated that over 1 million residents in the United Kingdom take warfarin; in excess of 20 million prescriptions for the anticoagulant are dispensed each year in the United States of America. Despite recent advances in the development of novel, alternative, oral antithrombotics it is likely that coumarins will be used widely for at least the next decade.

U2 - 10.1371/journal.pmed.0020342

DO - 10.1371/journal.pmed.0020342

M3 - Editorial

VL - 2

JO - PLoS Medicine

JF - PLoS Medicine

SN - 1549-1277

IS - 10

M1 - e342

ER -

Pharmacogenetics in the management of coumarin anticoagulant therapy: the way forward or an expensive diversion?

Abstract

Access to Document

Fingerprint

Cite this